.jpg?format=webp&width=780)
Delayed diagnosis is common in interstitial lung diseases (ILDs) and is associated with decreased quality of life and a poor prognosis. Early diagnosis and initiation of appropriate management could improve patient outcomes. Studies in idiopathic pulmonary fibrosis (IPF) demonstrated that antifibrotic therapies also slow disease progression in patients with more preserved lung function. Interstitial lung abnormalities (ILAs) found incidentally on computed tomography (CT) performed for other purposes, such as lung cancer screening or diagnostic cardiac CT, may facilitate early diagnosis of ILD, allowing for early treatment and removal of triggers that drive ILD progression. However, ILAs are relatively frequent, especially in older subjects. Systematic evaluation of population-based and lung cancer–screening cohorts showed a prevalence of ILAs of 4–9% in (former) smokers and 2–7% in never-smokers. With the increasing use of CT scans, clinicians are confronted with the question, “what to do with this person with ILAs?” Risk stratification of ILAs is urgently needed to differentiate two subsets ILAs with a high likelihood of progression to clinically relevant ILD; versus ILAs that pose no such risk and do not need further evaluation and follow-up.
Like
Save
Share